<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95388</article-id><article-id pub-id-type="doi">10.26442/20751753.2020.12.200562</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Targeted prostate biopsy in the diagnosis of prostate cancer: results from a prospective cohort study</article-title><trans-title-group xml:lang="ru"><trans-title>Таргетная биопсия простаты в диагностике рака предстательной железы: результаты проспективного группового исследования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Okishev</surname><given-names>Artem V.</given-names></name><name xml:lang="ru"><surname>Окишев</surname><given-names>Артем Вячеславович</given-names></name></name-alternatives><bio xml:lang="ru"><p>уролог</p></bio><email>okishev.art@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Govorov</surname><given-names>Alexander V.</given-names></name><name xml:lang="ru"><surname>Говоров</surname><given-names>Александр Викторович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vasilyev</surname><given-names>Alexander O.</given-names></name><name xml:lang="ru"><surname>Васильев</surname><given-names>Александр Олегович</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, ассистент каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sadchenko</surname><given-names>Anton V.</given-names></name><name xml:lang="ru"><surname>Садченко</surname><given-names>Антон Владимирович</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, уролог</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kolontarev</surname><given-names>Konstantin B.</given-names></name><name xml:lang="ru"><surname>Колонтарев</surname><given-names>Константин Борисович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bormotin</surname><given-names>Alexey V.</given-names></name><name xml:lang="ru"><surname>Бормотин</surname><given-names>Алексей Владимирович</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kim</surname><given-names>Yuriy A.</given-names></name><name xml:lang="ru"><surname>Ким</surname><given-names>Юрий Александрович</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант каф. урологии</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kizun</surname><given-names>Boris A.</given-names></name><name xml:lang="ru"><surname>Кузин</surname><given-names>Борис Александрович</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ramazanov</surname><given-names>Kerim K.</given-names></name><name xml:lang="ru"><surname>Рамазанов</surname><given-names>Керим Керимханович</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант каф. урологии</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pushkar</surname><given-names>Dmitriy Y</given-names></name><name xml:lang="ru"><surname>Пушкарь</surname><given-names>Дмитрий Юрьевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, зав. каф. урологии</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Spasokukotsky City Clinical Hospital</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Городская клиническая больница им. С.И. Спасокукоцкого» Департамента здравоохранения г. Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Yevdokimov Moscow State University of Medicine and Dentistry</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Medical and Sanitary Unit of the Ministry of Internal Affairs of the Russian Federation for the City of Moscow</institution></aff><aff><institution xml:lang="ru">ФКУЗ «Медико-санитарная часть Министерства внутренних дел Российской Федерации по городу Москве»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2020</year></pub-date><volume>22</volume><issue>12</issue><issue-title xml:lang="en">VOL 22, NO12 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 22, №12 (2020)</issue-title><fpage>69</fpage><lpage>73</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95388">https://consilium.orscience.ru/2075-1753/article/view/95388</self-uri><abstract xml:lang="en"><p>Background. Detection of prostate cancer by various targeting methods of prostate biopsy is an important problem now. Aim. To improve the detection of prostate cancer (PCa), compare the methods of targeted biopsy - cognitive biopsy guided by MRI with biopsy guided by histos-canning, using a randomized biopsy of the prostate from twelve cores as a control method. Materials and methods. A total of 145 respondents who underwent a randomized biopsy of the prostate in combination with targeted techniques were divided into 3 samples in accordance with the methods of targeted biopsy. In the results, the detectability by targeted methods was compared with each other and with a randomized biopsy as a control method. The results were subjected to statistical processing in order to form the conclusions of the study. Results. The detection rate of prostate cancer in the cognitive biopsy group was 64.4%, in the histofusion group - 51.1%, in the cognitive biopsy with histofusion group - 69% (p&lt;0.05). The detection of PCa when comparing positive targeted biopsies did not differ statistically significantly between the methods (38 and 36%, p=0.05). The percentage of positive biopsies was higher with histofusion biopsy (34.2%) than with cognitive biopsy (29.7%), the incidence of clinically significant cancer was higher according to the results of targeted methods compared with randomized biopsy (73% vs 37.5%, p&lt;0.05). The highest complication rate with the combined use of the studied targeting techniques was 13.6%, while all complications belonged to the 1st category according to Clavien-Dindo. Conclusion. To optimize the diagnosis of prostate cancer, it is advisable to use a combination of targeted and “randomized” cores. The combination of the targeted methods studied has been shown to be effective and safe. Carrying out a histofusion biopsy using a unified technique allows obtaining information on the clinical and morphological characteristics of prostate adenocarcinoma, which in terms of prognostic value is practically not inferior to the data of a cognitive biopsy performed taking into account the results of MRI. The use of targeted prostate biopsy methods increases the detection of clinically significant prostate cancer without adversely affecting the safety of the procedure in conjunction with standard prostate biopsy.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Улучшить выявляемость рака предстательной железы (РПЖ), сравнить методики таргетной биопсии - когнитивную биопсию под контролем магнитно-резонансной томографии с биопсией под контролем гистосканирования, используя в качестве контрольного метода рандомизированную биопсию простаты из 12 точек. Материалы и методы. 145 респондентов, перенесших рандомизированную биопсию простаты в сочетании с таргетными методиками, разделены на 3 выборки в соответствии с методами таргетной биопсии. В результате выявляемость РПЖ таргетными методами сравнили между собой и с рандомизированной биопсией в качестве контрольного метода. Результаты подвергнуты статистической обработке с целью формирования выводов исследования. Результаты. Выявляемость РПЖ в группе когнитивной биопсии составила 64,4%, в группе гистофьюжн-биопсии - 51,1%, в группе когнитивной биопсии с гистофьюжн - 69% (р&lt;0,05). Выявляемость РПЖ при сравнении положительных таргетных биоптатов статистически значимо не отличалась между методами (38 и 36%, р=0,05). Процент позитивных биоптатов оказался выше при выполнении гистофьюжн-биопсии (34,2%), чем при когнитивной биопсии (29,7%), частота клинически значимого рака выше по результатам таргетных методов по сравнению с рандомизированной биопсией (73% против 37,5%, р&lt;0,05). Максимальная частота осложнений при сочетанном применении изучаемых прицельных методик составила 13,6%, при том что все осложнения относились к 1-й категории по шкале Clavien-Dindo. Заключение. Для оптимизации диагностики РПЖ целесообразно использовать сочетание прицельных и «рандомизированных» вколов. Сочетание изученных таргетных методов продемонстрировало высокую эффективность и безопасность. Проведение гистофьюжн-биопсии по унифицированной методике позволяет получить информацию о клинико-морфологических характеристиках аденокарциномы простаты, по прогностической ценности практически не уступающую данным когнитивной биопсии, выполняемой с учетом результатов магнитно-резонансной томографии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>histofusion</kwd><kwd>histoscanning</kwd><kwd>targeted biopsy of prostate</kwd><kwd>targeted biopsy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гистофьюжн</kwd><kwd>гистосканирование</kwd><kwd>таргетная биопсия предстательной железы</kwd><kwd>прицельная биопсия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Available from: https://gco.iarc.fr/today/</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Available from: https://gco.iarc.fr/today/online-analysis-table</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Available from: https://gco.iarc.fr/tomorrow/graphic-line</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology 2019.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22:746-57.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015. Version 2. Eur Urol 2016; 69 (1): 16-40.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Turkbey B et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76 (3): 340-51.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Thompson JE, Moses D, Shnier R et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014; 192: 67-74.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rouviere O et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20: 100.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kasivisvanathan V et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018; 378: 1767.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Van der Leest M et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multipara-metric Prostate Resonance Imaging with Subsequent Magnetic Resonance guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol 2019; 75: 570.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Braeckman J, Autier P, Garbar C et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 2008; 101: 293-8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Javed S, Chadwick E, Edwards AA et al. Does prostate HistoScanningTM play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int 2014; 114 (4): 541-8.</mixed-citation></ref></ref-list></back></article>
